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Abstract
Objectives: Topical treatment with aminosalicylates and/or 
budesonide was shown to be highly effective in patients 
with ulcerative colitis (UC), while reducing the likelihood of 
systemic adverse effects. However, previous research has 
shown that topical treatment is clearly underused. We aimed 
to evaluate the use of topical therapy in the real-world set-
ting. Methods: This is an observational study based on claims 
data of 201 Swiss adult patients who were hospitalized for 
UC between 2012 and 2014 and who were then followed for 
1 year. A variety of factors presumably associated with topi-
cal treatment were examined. Annual health care utilization 
(UC-related medications, diagnostic procedures, consulta-
tions, and rehospitalizations) of patients with versus without 
topical therapy was compared. Results: Of the 201 hospital-
ized UC patients, 82 (40.8%) were treated with topical 5-ace-
tylsalicylic acid (ASA) and/or topical rectal steroids. The main 
factors significantly and positively associated with receiving 
topical treatment were the use of topical treatment in the 
year prior to the hospitalization, receiving oral 5-ASA, and 
living in an urban area. The mode of administration was fur-
ther related to the language area. Patients with topical ther-
apy significantly more often received other UC-related med-
ications, such as combinations with systemic steroids. They 
significantly more often underwent colonoscopies and cal-
protectin measurements, and more often consulted a gas-
troenterologist in the follow-up, while there was no signifi-
cant difference regarding rehospitalizations. Conclusions: 
Topical treatment is underused in patients with UC, which 
stands in contrast to the current European Crohn’s and Coli-
tis Organization guidelines. Patients’ preferences and con-
siderations need to be taken into account when prescribing 
medical therapy. © 2019 S. Karger AG, Basel
Introduction
Ulcerative colitis (UC) is a chronic relapsing inflam-
matory disorder of the colon. The etiology and patho-
physiology of UC are not yet entirely understood, but im-
munological and environmental factors along with genet-
ic susceptibility seem to mainly be responsible for the 
onset of UC [1, 2]. The prevalence of UC is estimated to 
be around 260–500/100,000 in Western countries, and 
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prevalence seems to increase over time [3–5]. UC always 
involves the rectum and shows variable extension to the 
left side (left-sided colitis) or the entire colon (pancolitis). 
More than two thirds of UC patients in population-based 
studies exhibit only a proctitis/proctosigmoiditis or left-
sided colitis whereas about one third of patients have ex-
tensive colitis at diagnosis [6–8]. 5-Aminosalicylic acid 
products (5-ASA; mesalazine or mesalamine) are consid-
ered to be first-line treatment in mild to moderate UC, 
irrespective of the disease localization [9–12]. In patients 
with proctitis or left-sided colitis, topical applications of 
5-ASA as suppository, enema, or foam preparation were 
shown to be more effective compared with oral treatment 
[9, 13, 14]. Rectally administered 5-ASA was superior to 
rectal steroids, while rectal steroids are superior to placebo 
in this situation [15–19]. In contrast, a meta-analysis by 
Manguso and Balzano [20] found similar efficacy of rectal 
steroids (beclomethasone dipropionate) and topical 
5-ASA in patients with distal mild to moderate UC. More-
over, a previous study has found a beneficial effect of a 
combined oral and topical treatment also in patients with 
pancolitis [21]. Topical treatment (5-ASA and/or ste-
roids) is associated with fewer side effects compared with 
a systemic administration, because rectally administered 
medications deliver a high dose of the active drug com-
pound directly to the site of inflammation [22, 23]. In the 
study by Seibold et al. [22], 334/790 (42.3%) patients had 
a past topical treatment. Side effects were experienced in 
7.5% of these patients, compared to 48.5% in patients with 
immunomodulators, 24% in patients with tumor necrosis 
factor (TNF) antagonists, and 13.1% in patients with oral 
5-ASA [22]. However, low adherence levels result in inef-
fective disease control and an increased risk of acute flares 
[24, 25]. The 5-ASA adherence rate was low in real-world 
practice, and it was significantly lower in topical therapy 
with enema compared with oral therapy [26]. Therefore, 
patients’ preferences and considerations need to be taken 
into account when prescribing medical therapy. Accord-
ing to previous findings, patients clearly preferred foam 
preparations, with respect to steroids, as well as with re-
spect to 5-ASA medications [27, 28].
In summary, topical treatment was shown to be highly 
effective, while reducing the likelihood of systemic ad-
verse effects. Especially patients with proctitis, rectosig-
moiditis, or left-sided colitis could benefit from topical 
therapy. However, previous research has shown that top-
ical treatment is clearly underused in a cohort of Swiss 
patients who were mainly treated in a university hospital 
setting and in a US setting, respectively [22, 29]. As of yet, 
little is known about the frequency of topical treatment 
and the factors associated with topical therapy in the real-
life setting.
We therefore aimed to examine the proportion of UC 
patients treated with topical therapies, the mode of ad-
ministration of topical therapy, as well as the factors as-
sociated with topical treatment in a real-world setting. 
Moreover, we aimed to compare the utilization of various 
health care resources (UC-related medications, diagnos-
tic procedures, consultations, and rehospitalizations) in 
the year following UC-related hospitalization in patients 
with versus without topical therapy.
Methods
Study Design and Study Population
This is an observational study based on claims data of the Hel-
sana Group, one of the leading insurance companies in Switzer-
land. Helsana provides insurance coverage for about 1.2 million 
inhabitants in Switzerland which roughly corresponds to 15% of 
the entire Swiss population (which currently counts 8 million in-
habitants). Patients hospitalized for UC were followed for 1 year, 
thereby comparing patients with and without topical therapy with 
5-ASA and/or rectal steroids. We focused on UC patients who re-
quired a hospitalization as only in this population the UC diagno-
sis is coded as such whereas it would be only approximative in UC 
outpatients never requiring a hospitalization (see methods below) 
[30, 31]. The year before the index hospitalization was also includ-
ed in order to examine the prestationary medical therapies. The 
study population consists of 256 adult UC patients who were hos-
pitalized with a main diagnosis of UC between January 1st, 2012, 
and December 31st, 2014. The main diagnosis of UC means that 
the main reason for the hospitalization was the underlying UC. 
Fourteen (5.4%) patients aged 17 years and younger, 14 patients 
who died during the follow-up, as well as 27 (10.5%) patients with 
missing data (i.e., patients living abroad, lump sums used for re-
imbursement of nursing home residents, or no full insurance cov-
erage at Helsana Group for the observation time of 2 years) were 
excluded. As such, a total of 201 UC patients were included for 
analysis.
The present study falls outside the scope of the Swiss Federal 
Act on Research involving Human Beings (Human Research Act), 
as the study is retrospective and based on anonymized routine ad-
ministrative health care claims data. Therefore, in accordance with 
the Swiss national ethical and legal regulations, no patient in-
formed consent and no further ethics approval were needed.
Measures
The organization of the Swiss health care system has been de-
scribed in a recent publication [31]. In Switzerland, a “diagnosis-
related group” system was introduced in 2012, which refers to 
ICD-10 codes and applied procedures. As such, UC patients were 
identified using the directional ICD-10 code K51. Main outcome 
variables comprise the proportion of patients with topical therapy, 
as well as the application form of the topical treatment. In addition, 
the need for further UC-related medications and/or combination 
therapies, the rate of rehospitalizations and disease-related rehos-
Baehler/Brüngger/Blozik/Vavricka/
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pitalizations, the number of face-to-face consultations by primary 
care physicians, gastroenterologists and/or other specialists, as 
well as the number of diagnostic procedures (computed tomogra-
phy scans, magnetic resonance imaging, X-ray, ultrasound, colo-
noscopy, and calprotectin measurement) in patients with versus 
without topical therapy were assessed. Further UC-related medi-
cations include: oral 5-ASA (mesalazine and sulfasalazine), immu-
nomodulators (methotrexate, azathioprine, and mercaptopurine), 
TNF antagonists (infliximab, adalimumab, golimumab), integrin 
inhibitors (vedolizumab, that got its first marketing approval in 
Switzerland in January 2015), and/or steroids (prednisone, oral 
budesonide). 
We analyzed the following factors regarding their association 
with the use of topical therapies: topical 5-ASA and/or rectal ste-
roid therapy in the year prior to the index hospitalization, patient 
characteristics (age group: 18–40, 41–60, and ≥61 years, sex, and 
additional chronic conditions), the type of patients’ health insur-
ance plan (managed care, deductible class, supplementary insur-
ance), and regional factors (type of residence and language area). 
Additional chronic conditions were identified based on the An-
atomical Therapeutic Chemical classification system, using an up-
dated measure of the Pharmacy-Based Cost Group model by Hu-
ber et al. [32]. Twenty-one additionally treated chronic conditions 
were considered: acid-related disorders, bone diseases (osteoporo-
sis), cancer, cardiovascular diseases (incl. hypertension), demen-
tia, diabetes mellitus, epilepsy, glaucoma, gout/hyperuricemia, 
HIV, hyperlipidemia, iron deficiency anemia, migraines, pain, 
Parkinson’s disease, psychological disorders (sleep disorders, de-
pression), psychoses, respiratory illness (asthma, COPD), rheuma-
tologic conditions, thyroid disorders, and tuberculosis.
Statistical Analysis
Descriptive statistics were used to evaluate differences between 
the characteristics of UC patients with and without topical treat-
ment using Fisher’s exact test for dichotomous variables, Wilcox-
on’s rank-sum test for continuous variables, and the χ2 test for cat-
egorical variables. Data are presented as percentages for categorical 
variables and as medians and interquartile ranges (showing the 1st 
and 3rd quartiles) for continuous variables. Logistic regression 
modeling was applied to examine factors that are associated with 
topical treatment and its different application forms. Multinomial 
logistic regression analysis was performed to determine the impact 
of sociodemographic, regional, and treatment-related variables on 
the odds of having no topical treatment, one mode of topical admin-
istration, or more than one mode of administration [33]. A thresh-
old for statistical significance of p = 0.05 (two-sided) was utilized.
Results
Topical Treatment, Mode of Administration, and Its 
Associated Factors
The mean age of the study population was 54.3 (±20.4) 
years, and 44.8% were males. Descriptive statistics of the 
Table 1. Characteristics of the study population





Number 201 119 (59.2%) 82 (40.8%)
Female sex 111 (55.2%) 71 (59.7%) 40 (48.8%) ns
Age ns
18–40 years 53 (26.4%) 25 (21.0%) 28 (34.1%)
41–60 years 46 (22.9%) 26 (21.8%) 20 (24.4%)
>60 years 102 (50.7%) 68 (57.1%) 34 (41.5%)
Language area: German 168 (83.6%) 100 (84.0%) 68 (82.9%) ns
Language area: French/Italian 33 (16.4%) 19 (16.0%) 14 (17.1%)
Type of residence (urban area) 155 (77.1%) 84 (70.6%) 71 (86.6%) 0.010
Chronic condition (excl. UC; 0–1) 91 (45.3%) 45 (37.8%) 46 (56.1%) 0.007
2–4 chronic conditions 65 (32.3%) 39 (32.8%) 26 (31.7%)
≥5 chronic conditions 45 (22.4%) 35 (29.4%) 10 (12.2%)
Home care nursing dependency 33 (16.4%) 22 (18.5%) 11 (13.4%) ns
Health insurance plan
Managed care 93 (46.3%) 51 (42.9%) 42 (51.2%) ns
Higher deductible 18 (9.0%) 7 (5.9%) 11 (13.4%) ns
Supplementary hospital insurance 36 (17.9%) 25 (21.0%) 11 (13.4%) ns
Left-sided colitisa 68 (33.8%) 40 (33.6%) 28 (34.1%) ns
Previous topical therapy 63 (31.3%) 21 (17.6%) 42 (51.2%) <0.001
Surgery at index hospitalization 15 (7.5%) 10 (8.4%) 5 (6.1%) ns
p values, assigning the differences between UC patients with and without topical therapy, were calculated 
using Fisher’s exact test for dichotomous variables and the χ2 test for categorical variables. ns, not significant. 
a Including rectosigmoiditis, proctitis, and left-sided colitis.
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characteristics of patients with versus without topical 
treatment in the year after the hospitalization are present-
ed in Table 1. Of the 201 hospitalized adult patients with 
a main diagnosis of UC, 82 (40.8%) were treated with top-
ical 5-ASA and/or topical rectal steroids (Fig. 1). Ninety 
percent (74/82) of these patients had a combined oral and 
topical treatment. Looking solely at the 68 patients with 
rectosigmoiditis, proctitis or left-sided colitis, the pro-
portion of patients with topical treatment hardly changed 
(41.2% with topical treatment, Fig. 1). Topical treatment 
in the year prior to the UC-related hospitalization was 
found in 63/201 (31.3%) patients, whereby 32 patients re-
ceived 5-ASA, 12 patients received steroids, and 19 pa-
tients were treated with both drugs. Patients with topical 
therapy more often lived in an urban area and had fewer 
additional chronic conditions (Table 1). The proportions 
of patients with topical treatment by disease localization 
are shown in Table 2. In summary, 68 (33.8%) of UC pa-
tients suffered from a proctitis, a rectosigmoiditis or a 
left-sided colitis.
In the logistic regression model, the main factors sig-
nificantly associated with receiving topical treatment 
were the use of topical treatment in the year prior to the 
disease-related hospitalization, receiving oral 5-ASA, and 
living in an urban area (Table 3). In contrast, sociodemo-
graphic factors such as age and sex, as well as additional 
chronic conditions did not seem to play an important role 
in the multivariate model.
0 25 50
Share of patients with rectal therapy
Hospitalized adult patients with rectosigmoiditis,
proctitis or left-sided colitis
75 100%
0 25 50
All hospitalized adult patients
75 100%
Fig. 1. Proportion of UC patients with topical therapy in the year 
after index hospitalization. 
Table 2. Topical treatment according to disease location in the year 
after hospitalization




Number 201 119 (59.2%) 82 (40.8%)
Proctitis 10 (5.0%) 2 (1.7%) 8 (9.8%)
Rectosigmoiditis 14 (7.0%) 6 (5.0%) 8 (9.8%)
Left-sided colitis 44 (21.9%) 32 (26.9%) 12 (14.6%)
Extensive 
colitis/pancolitis 47 (23.4%) 30 (25.2%) 17 (20.7%)
Location not specified 86 (42.8%) 49 (41.2%) 37 (45.1%)
Table 3. Logistic regression modeling identifying sociodemo-
graphic and treatment-related factors associated with receiving 
topical treatment (n = 201) in the year after index hospitalization
OR (95% CI) p
Age >60 years 1.000
Age 18–40 years 0.993 (0.368–2.663) ns
Age 41–60 years 1.418 (0.578–3.467) ns
Female sex 0.628 (0.298–1.307) ns
Language area: French/Italian 0.799 (0.307–2.027) ns
Type of residence (urban area) 2.642 (1.124–6.582) 0.030
Managed care 1.048 (0.515–2.118) ns
Supplementary hospital insurance 0.505 (0.189–1.287) ns
Chronic condition (excl. UC; 0–1) 1.000
2–4 chronic conditions 0.695 (0.293–1.637) ns
≥5+ chronic conditions 0.460 (0.152–1.320) ns
Left-sided colitis 1.483 (0.705–3.161) ns
Previous topical therapy 4.791 (2.230–10.751) <0.001
5-ASA, oral 3.164 (1.497–6.892) 0.003
Thiopurines 1.063 (0.423–2.632) ns
TNF antagonists 2.238 (0.782–6.725) ns
Steroids, systemic 1.271 (0.544–2.951) ns
OR, odds ratio; CI, confidence interval; ns, not significant. 
Akaike information criterion = 240.49.







Enema 28 (34.1%) 6 (7.3%) 32 (39.0%)
Foam 27 (32.9%) 30 (36.6%) 46 (56.1%)
Suppositories 31 (37.8%) – 31 (37.8%)
Total 69 (84.1%) 33 (40.2%) 82 (100%) 
The total numbers may be lower than the sum of each 
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Overall, foam was the most prevalent application form 
in topical therapy (Table 4; Fig. 2). In logistic regression 
models, looking at factors associated with the mode of 
administration of topical treatment, pretreatment with 
topical 5-ASA and/or steroids was significantly and posi-
tively associated with receiving foam (OR = 2.67 [1.18–
6.22], p = 0.020) or suppositories (OR = 5.16 [1.97–14.50], 
p = 0.001), but not enema in the follow-up period. Receiv-
ing oral 5-ASA was also positively associated with taking 
foam (OR = 2.75 [1.17–6.87], p = 0.024) and/or enema 
(OR = 6.99 [2.29–25.56], p = 0.001) in the 1-year follow-
up. Living in the French or Italian region was significant-
ly and positively associated with receiving 5-ASA foam 
(OR = 3.29 [1.06–10.19], p = 0.037), and significantly and 
negatively associated with 5-ASA enema use (OR = 0.10 
[0.01–0.52], p = 0.017). Regarding disease location, left-
sided colitis was only significantly related to foam use 
(OR = 2.52 [1.13–5.73], p = 0.025). 
In the population with topical treatment, 23 (28.0%) 
patients used more than one mode to administer medica-
tions. In the multinomial logistic regression model, con-
trolling for age group, sex, further chronic conditions, 
disease location, language area, and further UC-related 
medications, patients with prior topical treatment had 4.6 
times higher odds of receiving topical treatment (CI = 
1.99–10.55), and 6 times higher odds of using more than 
one mode of administration (CI = 1.97–18.20). Treat-
ment with oral 5-ASA was also associated with higher 
Enema
Foam 5-ASA






Share of patients with rectal therapy and respective application form
75 100%
Fig. 2. Proportion of patients with topical 
therapy and respective application form in 
the year after index hospitalization.
Table 5. Medications and drug combinations in patients treated with and without topical therapy during the 
12-month follow-up (n = 201)





Number 201 119 (59.2%) 82 (40.8%)
5-ASA orally 109 (54.2%) 48 (40.3%) 61 (74.4%) <0.001
Thiopurines 69 (34.3%) 31 (26.1%) 38 (46.3%) 0.004
TNF antagonists 42 (20.9%) 18 (15.1%) 24 (29.3%) 0.021
Systemic steroids 128 (63.7%) 66 (55.5%) 62 (75.6%) 0.004
5-ASA + thiopurines 54 (26.9%) 19 (16.0%) 35 (42.7%) <0.001
5-ASA + biologics 32 (15.9%) 11 (9.2%) 21 (25.6%) 0.003
Thiopurines + biologics 24 (11.9%) 5 (4.2%) 19 (23.2%) <0.001
Thiopurines + biologics + 5-ASA 20 (10.0%) 4 (3.4%) 16 (19.5%) <0.001
Systemic steroids + 5-ASA 149 (74.1%) 75 (63.0%) 74 (90.2%) <0.001
Systemic steroids + thiopurines 133 (66.2%) 69 (58.0%) 64 (78.0%) 0.003
Systemic steroids + biologics 132 (65.7%) 68 (57.1%) 64 (78.0%) 0.002
p values, assigning the differences between UC patients with and without topical therapy, were calculated 
using Fisher’s exact test.
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odds of receiving topical treatment (OR = 3.20, CI = 1.42–
7.23). However, due to the wide confidence interval, re-
sults need to be interpreted with caution.
Health Care Utilization during the 1-Year Follow-Up
Patients with topical therapy significantly more often 
received all other UC-related medications, such as com-
binations with systemic steroids (Table 5). Integrin in-
hibitors were only found in 1 patient who additionally 
received TNF antagonists and topical treatment. Patients 
with topical treatment were also more likely to receive a 
higher number of further UC-related drug prescriptions, 
notably for systemic steroids and oral 5-ASA (results not 
shown).
Patients with topical therapy significantly more often 
underwent diagnostic procedures, especially colonosco-
pies and measurements of fecal calprotectin (Table 6). Pa-
tients treated with topical therapy had a significantly 
higher median number of face-to-face consultations, 
whereby the biggest difference was found for consulta-
tions with gastroenterologists (Table 7).
We found no significant difference between patients 
treated with and without topical therapy regarding rehos-
pitalizations (ever had a rehospitalization or the number 
of rehospitalizations) in the year following the index hos-
pitalization (Table 8). More than one third of all UC pa-
tients had at least one rehospitalization within 12 months 
after the index hospitalization. In the multivariate logistic 
regression model, there was again no significant differ-
ence regarding rehospitalization between patients with 
and without topical therapy, when controlling for age 
group, sex, further chronic conditions, disease location, 
language area, urbanity, patients’ health insurance plan, 
and further UC-related medications (results not shown).
Table 6. Diagnostic procedures in patients treated with and without topical therapy during the 12-month follow-
up after hospitalization (n = 201)





Number 201 119 (59.2%) 82 (40.8%)
Computer tomography 27 (13.4%) 15 (12.6%) 12 (14.6%) ns
Abdominal magnetic resonance imaging 10 (5.0%) 2 (1.7%) 8 (9.8%) 0.017
X-ray 4 (2.0%) 1 (0.8%) 3 (3.7%) ns
Abdominal ultrasound 66 (32.8%) 33 (27.7%) 33 (40.2%) ns
Colonoscopy 101 (50.2%) 45 (37.8%) 56 (68.3%) <0.001
Fecal calprotectin 46 (22.9%) 18 (15.1%) 28 (34.1%) 0.002
p values, assigning the differences between UC patients with and without topical therapy, were calculated 
using Fisher’s exact test. ns, not significant.
Table 7. Number of consultations in patients treated with and without topical therapy during the 12-month fol-
low-up (n = 201)





Number 201 119 (59.2%) 82 (40.8%)
Total consultations 23.0 (15.0–35.0) 21.0 (13.5–31.0) 26.0 (17.3–37.0) 0.013
By primary care physicians 9.0 (2.0–14.0) 8.0 (1.0–13.0) 9.5 (4.0–17.0) ns
By gastroenterologists 9.0 (3.0–14.0) 7.0 (2.0–11.0) 12.0 (4.3–18.0) 0.001
By other specialists 4.0 (1.0–11.0) 4.0 (1.0–10.5) 4.5 (1.0–11.0) ns
Results are expressed as medians with interquartile ranges in parentheses, except number. p values, assigning 
the differences between UC patients with and without topical therapy, were calculated using Wilcoxon’s rank-
sum test. ns, not significant.
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Discussion
In this study we present population-based real-life 
data on the use of topical therapies and health care con-
sumption in Swiss UC patients who were followed for 1 
year after an index hospitalization. Our analysis contains 
several clinically relevant messages. First, only 41% of UC 
patients (all disease locations) were treated with topical 
5-ASA and/or topical rectal steroids. Second, topical 
treatment in the year prior to the UC-related hospitaliza-
tion was found in only 31% of patients. Third, the main 
factors significantly and positively associated with receiv-
ing topical treatment were the use of topical treatment in 
the year prior to the hospitalization, receiving oral 5-ASA, 
and living in an urban area. Fourth, patients with topical 
therapy significantly more often received other UC-relat-
ed drugs, which points towards a severer disease pattern 
when compared to UC patients without topical therapies. 
And fifth, patients with topical therapies significantly 
more often consumed health care compared to patients 
without topical therapies. 
Based on the solid literature evidence, the current Eu-
ropean Crohn’s and Colitis Organization guidelines state 
that mild to moderately active UC (proctitis, left-sided 
colitis, and extensive colitis) should be treated with local 
5-ASA therapy (suppositories or enema, respectively) 
plus a combination of oral 5-ASA products [34]. The 
guidelines further state that patients with severe UC 
should be admitted to hospital for intensive treatment 
[35]. Topical treatment was shown to be highly effective, 
while reducing the likelihood of systemic adverse effects. 
In a follow-up study of a median of 6 years, combined oral 
and rectal treatment was clearly superior to oral treat-
ment alone in 84 UC patients, with no dropouts or side 
effects in either group [35]. Patients with a combined 
therapy had a significant reduction in the incidence of 
relapses [36]. Moreover, patients with a combined oral 
and rectal therapy had lower overall costs, because the 
higher drug costs were offset by 48% lower costs due to 
the reduction in relapses and due to no accruing costs for 
hospitalizations in the follow-up [36]. Our real-life data 
document an important underuse of local therapy that 
stands in clear contrast to the therapeutic guidelines [35]. 
Patients under topical treatment more often received oth-
er UC-related medications, had more endoscopies, and 
had more frequently consultations by gastroenterolo-
gists. Based on these observations we hypothesize that 
topical therapy was applied in patients with severer dis-
ease in combination with systemic steroids and biologics 
to more rapidly achieve a clinical response or remission, 
respectively. Of note, a recent paper by Singh et al. [36] 
showed that continuation of 5-ASA in moderate-to-se-
vere UC patients who were escalated to TNF antagonists 
did not improve clinical outcomes. Our data on the fre-
quency of topical treatments are in accordance with data 
from Seibold et al. [22], who showed that 334/790 (42.3%) 
of UC patients had a past topical treatment. The main dif-
ference between the two studies is that in the Seibold 
study UC patients were recruited in 80% of cases by gas-
troenterologists working in hospital while as in our study 
the results can be regarded as a population-based selec-
tion of hospitalized patients [12]. There might exist sev-
eral reasons from the side of the prescribing physicians 
and from the patients’ side as well to explain the underuse 
of local therapies in UC patients. First of all, it is possible 
that prescribing physicians are not sufficiently aware of 
the data demonstrating the efficacy and safety of the dif-
ferent forms of local therapy in UC. It is also possible that 
physicians, despite their knowledge of the data, fail to 
transport the important information onto the patient and 
empower them to use local therapies. On the patient’s 
side it is well possible that there exist psychosocial barri-
Table 8. Rehospitalizations in patients treated with and without topical therapy during the 12-month follow-up





Rehospitalization 74 (36.8%) 44 (37.0%) 30 (36.6%) ns
Number of rehospitalizations (median/IQR) 0 (0–1.0) 0 (0–1.0) 0 (0–1.0) ns
Surgery1 28 (37.8%) 24 (54.5%) 4 (13.3%) na
Disease-related surgery1 13 (18.3%) 10 (23.8%) 3 (10.3%) na
p values, assigning the differences between UC patients with and without topical therapy, were calculated 
using Fisher’s exact test for dichotomous variables and Wilcoxon’s rank-sum test for continuous variables. ns, 
not significant; na, not applicable; IQR, interquartile range. 1 In those 74 patients with at least 1 rehospitalization.
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ers that limit the use of local treatment. We claim that 
physicians prescribing local therapy should be proactive 
in informing patients regarding the efficacy and safety, 
but also take into account the patients’ preferences and 
considerations as low adherence levels result in ineffec-
tive disease control [24]. Several studies have evaluated 
the patient’s view regarding local therapy in UC. Even 
though steroid enemas and steroid foam were both shown 
to be effective in the treatment of distal UC, patients 
clearly preferred foam preparations [27]. Due to their 
higher volume, enemas are often less well tolerated than 
foam during acute flares and may cause pain and discom-
fort. In 233 patients with UC, 5-ASA foam was better ac-
cepted than 5-ASA enema, because it was more comfort-
able, interfered less with daily living and was well toler-
ated [28]. Treatment with 5-ASA suppositories was more 
effective and found to be more practical in patients with 
distal UC in comparison to treatment with hydrocorti-
sone foam [37]. The superiority of 5-ASA enemas and 
suppositories over topical steroids or oral therapies was 
confirmed by the results of a meta-analysis by Cohen and 
colleagues [17]. We conclude that every prescribing phy-
sician should be aware about the data regarding topical 
therapies and communicate them in a proactive way to 
the concerned patients. Treatment decisions should be 
made on a joint basis between prescribing physician and 
patient in order to achieve a patient empowerment with 
consecutively better adherence rates to the prescribed 
treatment which ultimately results in better clinical out-
comes [38, 39].
According to our analysis, 50.2% of all patients had a 
colonoscopy within 1 year after the disease-related hospi-
talization, whereby the proportion was significantly high-
er in patients with topical treatment. Other disease-mon-
itoring tools such as measurement of fecal calprotectin 
were also significantly more frequently found in UC pa-
tients with topical treatment. We assume that UC patients 
with topical disease represented a cohort characterized by 
severer disease activity compared to patients without lo-
cal treatment and therefore indeed were in need of more 
frequently applied monitoring of endoscopic activity. 
More than one third of the patients of our cohort were 
rehospitalized within 1 year after the index hospitaliza-
tion without detecting a difference between patients with 
and without topical treatment. A total of 18% of rehospi-
talized patients underwent UC-related surgery; again no 
difference was found between patients with and without 
topical treatment. In a Canadian study, 18.5–20.3% of UC 
patients were rehospitalized at least once per year, where-
by, 55% had to undergo a major surgery [40].
Our population-based study has several strengths and 
also some limitations. The analyses are based on health 
insurance claims data that cover a broad range of highly 
reliable and comprehensive information on in- and out-
patient care. These data were not collected by means of 
self-reports, and results were therefore not distorted due 
to recall bias. As a first limitation, we were not able to 
consider medications applied during hospitalizations. 
Additionally, variables such as disease activity, disease 
duration, disease evolution, as well as patients’ preferenc-
es were not assessed [41]. The study looks at health care 
utilization in the year following UC-related hospitaliza-
tion, independently of the reason for use. As such, the 
entire health care utilization may not be necessarily re-
lated to UC treatment. Secondly, as a limitation that is 
inherent to our study methodology, we had to focus on 
the population of UC patients in need of a hospitalization. 
Our target population might be characterized by a disease 
course that is severer when compared to UC patients not 
in need of a hospitalization. As such, all results are valid 
only for inpatients with UC and can therefore not be gen-
eralized to the entire population of UC patients in Swit-
zerland. Third, the data we present in this paper are spe-
cific for Switzerland and cannot be generalized to other 
countries. 
In conclusion, our real-life data show that topical ther-
apies are clearly underused in UC patients which stands 
in sharp contrast with the current European Crohn’s and 
Colitis Organization guidelines on the management of 
UC. A good adherence to local therapies in UC patients 
has shown to save health care costs by reducing the risk 
of flares and hospitalizations. Factors on the physicans’ 
and patients’ side hampering the use of local therapies 
need to be further evaluated. 
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